Lupus erythematosus and porphyria. Coexistence in seven patients.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000437:Alcoholism / Q000150:complications; D000974:Antibodies, Antinuclear / Q000032:analysis; D001485:Basement Membrane / Q000276:immunology; D003165:Complement System Proteins / Q000032:analysis; D005234:Fatty Liver / Q000209:etiology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007970:Leukopenia / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011164:Porphyrias / Q000150:complications* / Q000276:immunology / Q000628:therapy; D011166:Porphyrins / Q000652:urine; D011241:Prednisone / Q000627:therapeutic use; D012867:Skin / Q000276:immunology; D014222:Triamcinolone Acetonide / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000974:Antibodies, Antinuclear; D007074:Immunoglobulin G; D011166:Porphyrins; D003165:Complement System Proteins; D014222:Triamcinolone Acetonide; D011241:Prednisone